Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Linxweiler

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Visceral Medicine|May 12, 2021
<i>SEC62</i> and <i>SEC63</i> Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver TissueMarkus Casper, Maximilian Linxweiler, Johannes Linxweiler, et al.
Urologia Internationalis|July 9, 2020
Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide SurveyMatthias Saar, Johannes Linxweiler, Angelika Borkowetz, et al.
Cancers|June 10, 2022
Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot ExperienceFlorian Rosar, Hanna Bader, Mark Bartholomä, et al.
Cancers|July 2, 2021
Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney FunctionFlorian Rosar, Niklas Kochems, Mark Bartholomä, et al.
Theranostics|March 23, 2021
Molecular imaging and biochemical response assessment after a single cycle of [<sup>225</sup>Ac]Ac-PSMA-617/[<sup>177</sup>Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [<sup>177</sup>Lu]Lu-PSMA-617 monotherapyFlorian Rosar, Fabian Hau, Mark Bartholomä, et al.
Der Urologe. Ausg. A|September 16, 2020
[When a urological emergency indicates an internal medical crisis : Priapism as the first clinical manifestation of leukemia]Muhammad Abdeen, Martin Janssen, Zaid Al-Kailani, et al.
World Journal of Surgical Oncology|February 22, 2018
Kidney autotransplantation after nephrectomy and work bench surgery as an ultimate approach to nephron-sparing surgeryMartin W W Janssen, Johannes Linxweiler, Ines Philipps, et al.
BJU International|May 18, 2018
Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-upTurkan Hajili, Carsten H Ohlmann, Johannes Linxweiler, et al.
Pharmaceutics|June 2, 2021
Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor PrognosisFlorian Rosar, Jonas Krause, Mark Bartholomä, et al.
Biomolecules|August 27, 2021
Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand TherapyFadi Khreish, Mona Wiessner, Florian Rosar, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Visceral Medicine|May 12, 2021
<i>SEC62</i> and <i>SEC63</i> Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver TissueMarkus Casper, Maximilian Linxweiler, Johannes Linxweiler, et al.
Urologia Internationalis|July 9, 2020
Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide SurveyMatthias Saar, Johannes Linxweiler, Angelika Borkowetz, et al.
Cancers|June 10, 2022
Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot ExperienceFlorian Rosar, Hanna Bader, Mark Bartholomä, et al.
Cancers|July 2, 2021
Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney FunctionFlorian Rosar, Niklas Kochems, Mark Bartholomä, et al.
Theranostics|March 23, 2021
Molecular imaging and biochemical response assessment after a single cycle of [<sup>225</sup>Ac]Ac-PSMA-617/[<sup>177</sup>Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [<sup>177</sup>Lu]Lu-PSMA-617 monotherapyFlorian Rosar, Fabian Hau, Mark Bartholomä, et al.
Der Urologe. Ausg. A|September 16, 2020
[When a urological emergency indicates an internal medical crisis : Priapism as the first clinical manifestation of leukemia]Muhammad Abdeen, Martin Janssen, Zaid Al-Kailani, et al.
World Journal of Surgical Oncology|February 22, 2018
Kidney autotransplantation after nephrectomy and work bench surgery as an ultimate approach to nephron-sparing surgeryMartin W W Janssen, Johannes Linxweiler, Ines Philipps, et al.
BJU International|May 18, 2018
Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-upTurkan Hajili, Carsten H Ohlmann, Johannes Linxweiler, et al.
Pharmaceutics|June 2, 2021
Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor PrognosisFlorian Rosar, Jonas Krause, Mark Bartholomä, et al.
Biomolecules|August 27, 2021
Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand TherapyFadi Khreish, Mona Wiessner, Florian Rosar, et al.
Pageof 6